Related Experiment Video
Updated: Jun 3, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
The PTH (1-84)/non-PTH (1-84) ratio is a risk factor for cardiovascular events in hemodialysis patients
1Department of Internal Medicine IV, Nephrology and Hypertension, Innsbruck Medical University, Innsbruck, Austria.
Insights
The parathyroid hormone (PTH) ratio may help predict cardiovascular events in hemodialysis patients. A higher PTH ratio is linked to increased cardiovascular risk, suggesting its utility in risk assessment.
Area of Science:
- Nephrology
- Cardiology
- Endocrinology
Background:
- Cardiovascular disease (CVD) is a leading cause of mortality in hemodialysis patients.
- The parathyroid hormone (PTH) (1-84)/non-PTH (1-84) ratio (PTH ratio) is a novel biomarker.
- The potential of the PTH ratio to assess cardiovascular risk in this population remains unclear.
Purpose of the Study:
- To investigate the association between the PTH ratio and cardiovascular events (CVE) in hemodialysis patients.
- To determine if the PTH ratio can serve as a predictor of cardiovascular risk.
Main Methods:
- Prospective cohort study of 70 prevalent hemodialysis patients followed for up to 4 years.
- Baseline PTH ratio measurement.
- Primary outcomes: cardiovascular events (CVE) and all-cause mortality.
- Cox proportional hazards modeling to assess risk association.
Main Results:
- A PTH ratio > 1 was observed in 49% of patients.
- Patients with CVE exhibited a significantly higher PTH ratio compared to event-free patients (p=0.033).
- A PTH ratio > 1 was associated with a higher incidence of CVE (53% vs. 22%, p=0.013) and shorter event-free survival (p=0.032).
- Higher PTH ratio independently predicted elevated CVE risk (HR=3.2, p=0.04).
Conclusions:
- An elevated PTH (1-84)/non-PTH (1-84) ratio is significantly associated with increased cardiovascular risk in hemodialysis patients.
- The PTH ratio shows promise as a valuable tool for cardiovascular risk stratification in this high-risk group.
Background:
We hypothesized that the PTH (1-84)/non-PTH (1-84) ratio (PTH ratio) might help to assess cardiovascular risk in hemodialysis patients.
Methods:
In this prospective cohort study 70 prevalent hemodialysis patients were followed up to 4 years. The PTH ratio was determined at baseline. Primary outcomes were cardiovascular events (CVE) and all-cause mortality. Cumulative event-free survival was compared between patients with a ratio < 1 and those with a ratio > 1. The risk-association of the PTH ratio with CVE was examined using an adjusted Multiple Cox Proportional Hazards model.
Results:
A PTH ratio > 1 was found in 34 patients (49%). During follow-up 26 patients suffered a CVE. Patients with a CVE showed a higher ratio than patients with event-free survival (p = 0.033). In patients with a ratio > 1 a significantly higher number of CVE occurred (53 vs. 22%; p = 0.013), and these patients showed a significantly shorter event-free survival (p = 0.032). In an adjusted Cox-proportional hazards model a higher PTH ratio was found to be independently associated with an elevated risk for CVE (HR = 3.2; 95% CI 1.06 - 13.63; p = 0.04).
Conclusions:
A higher PTH (1-84)/non-PTH (1-84) ratio is associated with an increased risk for CVE in hemodialysis patients and might therefore be useful for cardiovascular risk estimation in this population.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Hazard Ratio
For example, in a clinical trial evaluating a...
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Peritoneal Dialysis III: Nursing Management
Serum Studies: Renal Function Tests
